Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease

Circulation Journal

Volumn 73, Issue 5, 2009, Pages 948-954

  Hsieh, Ching Jung ^a,b   Wang, Pei Wen ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adiponectin; CD40; Cilostazol; Diabetes mellitus; Peripheral arterial disease

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CD40 ANTIGEN; CILOSTAZOL; PLACEBO;

ADULT; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADIPONECTIN; AGED; AGED, 80 AND OVER; ANKLE; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CD40 LIGAND; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LINEAR MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; SINGLE-BLIND METHOD; TETRAZOLES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 65649094040     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0905     Document Type: Article

References (35)

1. Faglia E, Caravaggi C, Marchetti R, Mingardi R, Morabito A, Piaggesi A, et al, SCAR (SCreening for ARteriopathy) study group. Screening for peripheral arterial disease by means of the ankle-brachial index in newly diagnosed Type 2 diabetic patients. Diabet Med 2005; 22: 1310-1314.
2. Feringa HH, Karagiannis SE, Vidakovic R, Elhendy A, Schouten O, Boersma E, et al. Glycemic control, lipid-lowering treatment, and prognosis in diabetic patients with peripheral atherosclerotic disease. Ann Vasc Surg 2007; 21: 780-789. (Pubitemid 350017872)
3. Tseng CH. Prevalence and risk factors of peripheral arterial obstructive disease in Taiwanese type 2 diabetic patients Angiology 2003; 54: 331-338. (Pubitemid 36578465)
4. Tseng CH. Sex difference in the distribution of atherosclerotic risk factors and their association with peripheral arterial disease in Taiwanese type 2 diabetic patients. Circ J 2007; 71: 1131-1136. (Pubitemid 46998032)
5. Nishida M, Moriyama T, Ishii K, Takashima S, Yoshizaki K, Sugita Y, et al. Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis. Clin Chim Acta 2007; 384: 99-104. (Pubitemid 47248651)
6. Iwashima Y, Horio T, Suauki Y, Kihara S, Rakugi H, Kangawa K, et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 2006; 188: 384-390. (Pubitemid 44301128)
7. Plutzky J. Inflammation in atherosclerosis and diabetes mellitus. Rev Endocr Metab Disord 2004; 5: 255-259. (Pubitemid 38903583)
8. de Lemos JA, Zirlik A, Schonbeck U, Varo N, Murphy SA, Khera A, et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: Results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2005; 25: 2192-2196. (Pubitemid 41416320)
9. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness and treatment in primary care. JAMA 2001; 286: 1317-1324. (Pubitemid 33015522)
10. Aso Y, Okumura K, Inoue T, Matsutomo R, Yoshida N, Wakabayashi S, et al. Results of blood inflammatory markers are associated more strongly with toe-brachial index than with ankle-brachial index in patients with type 2 diabetes. Diabetes Care 2004; 27: 1381-1386. (Pubitemid 38679987)
11. Guldiken S, Demir, M, Arikan E, Turgut B, Azcan S, Gerenli M, et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 2007; 119: 79-84.
12. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol independent of body mass index, in the Japanese population. Clin Sci 2002; 13: 137-142.
13. Dieplinger B, Poelz W, Halmayer M, Mueller T. Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease. Clin Chem Lab Med 2006; 44: 830-833. (Pubitemid 43911555)
14. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 2005; 25: 2428-2434. (Pubitemid 41552666)
15. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: A novel target of thiazolidinediones. Circulation 2003; 107: 2664-2669. (Pubitemid 36667238)
16. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-1957. (Pubitemid 36506065)
17. Lee WJ, Sheu WH, Chen YT, Liu TJ, Liang KW, Ting CT, et al. Circulating CD40 ligand is elevated only in patients with more advanced symptomatic peripheral arterial diseases. Thromb Res 2006; 118: 619-626. (Pubitemid 44414952)
18. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 2005; 313: 502-509. (Pubitemid 40604148)
19. Agrawal NK, Maiti R, Dash D, Pandey BL. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol Res 2007; 56: 118-123. (Pubitemid 47302794)
20. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006; 189: 350-357. (Pubitemid 44634499)
21. Hong KW, Kim KY, Shin HK, Lee JH, Choi JM, Kwak YG, et al. Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element-binding protein phosphorylation. J Pharmacol Exp Ther 2003; 306: 1182-1190. (Pubitemid 37025330)
22. Park SY, Lee JH, Kim KY, Kim EK, Yun SJ, Kim CD, et al. Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-γ transcription (abstract). Atherosclerosis 2008; 201: 258-265.
23. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Cilostazol for Restenosis Trial (CREST) Investigators: Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-2832.
24. Jacoby D, Mohler ER III. Drug treatment of intermittent claudication. Drugs 2004; 64: 1657-1670. (Pubitemid 39128003)
25. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998; 18: 1942-1947. (Pubitemid 28565758)
26. Ikewaki K, Mochizuki K, Iwasaki M, Nishide R, Mochizuki S, Tada N. Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus. Metabolism 2002; 51: 1348-1354. (Pubitemid 35174158)
27. Nomura S, Inami N, Iwasaka T, Liu Y. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: Therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets 2004; 15: 167-172. (Pubitemid 38651028)
28. Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, et al Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007; 71: 1867-1872 (Pubitemid 350261408)
29. Ahn JC, Song WH, Kwon JA, Park CG, Seo HA, Oh DJ, et al. Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean J Intern Med 2004; 19: 230-236. (Pubitemid 41237457)
30. Wang F, Gao L, Gong B, Hu J, Li M, Guan Q, et al. Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol. Can J Physiol Pharmacol 2008; 86: 465-471.
31. Kroger K. Dyslipoproteinemia and peripheral arterial occlusive disease. Angiology 2004; 55: 135-138. (Pubitemid 38337744)
32. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495. (Pubitemid 38680001)
33. Mita T, Otsuka A, Azuma K, Uchida T, Ogihara T, Fujitani Y, et al. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2007; 358: 679-685. (Pubitemid 46802446)
34. Watada H, Azuma K, Kawamori R. Glucose fluctuation on the progression of diabetic microangiopathy: New findings from monocyte adhesion to endothelial cells. Diabetes Res Clin Pract 2007; 77: S58-S61. (Pubitemid 47212554)
35. Wikström J, Hansen T, Johansson L, Lind L, Ahlström H. Ankle brachial index <0.9 underestimates the prevalence of peripheral artery occlusive disease assessed with whole-body magnetic resonance angiography in the elderly. Acta Radiol 2008; 49: 143-149.